Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Lexicon Pharmaceuticals is advancing its pipeline with multiple potential catalysts expected in 2026, including the completion of the SONATA-HCM study and the resubmission of the NDA for Zynquista [2][3][4] Business and Pipeline Highlights - The SONATA-HCM pivotal Phase 3 study for sotagliflozin is on track, targeting enrollment of 500 patients, with completion expected in mid-2026 and topline results anticipated in Q1 2027 [3] - Zynquista (sotagliflozin) for Type 1 Diabetes is set for NDA resubmission in 2026, contingent on FDA feedback and additional clinical data from the STENO1 study [4][5] - Lexicon is pursuing international expansion for sotagliflozin, with regulatory approval already received in the UAE and applications submitted in other markets including Canada and Australia [4][6] Financial Updates - A $10 million milestone payment was triggered from a licensing agreement with Novo Nordisk for LX9851, with potential for an additional $20 million in milestone payments in 2026 [11] - Lexicon ended 2025 with cash, investments, and restricted cash totaling $125.2 million, which is sufficient to support operations into 2027 [11]